Nyse rcus.

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Terry Rosen ...Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September:HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...HAYWARD, Calif., August 23, 2023--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...

Anyone interested in Arcus Biosciences, Inc. (NYSE:RCUS) should probably be aware that the Co-Founder, Terry Rosen, recently divested US$211k worth of shares in the company, at an average price of ...

Arcus Biosciences, Inc. (RCUS). NYSE: RCUS · IEX Real-Time Price · USD.The RCUS shares have gain 14.30% over the last week, with a monthly amount glided 1.58%, and seem. At the time of writing, Arcus Biosciences Inc [RCUS] stock is trading at $16.07, up 6.71%. It is a good measure of the stock's recent performance to check whether the stock's short-term value is rising or falling. The RCUS shares have …HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...The latest price target for . Arcus Biosciences (NYSE: RCUS) was reported by Cantor Fitzgerald on November 8, 2023.The analyst firm set a price target for $36.00 expecting RCUS to rise to within ...

Mar 23, 2023 · Arcus Biosciences ( NYSE: RCUS) is a biopharmaceutical company specializing in cancer therapeutics that are operating at the clinical stage. Their lead candidate, domvanalimab, has displayed ...

Arcus Biosciences, Inc. (NYSE:RCUS) shares were also up, gaining 25% to $21.83. Citigroup maintained Arcus Biosciences with a Buy. Equities Trading DOWN.

The company has an average price target of $46.33 with a high of $70.00. Webull offers RCUS Ent Holdg (RCUS) historical stock prices, in-depth market analysis, NYSE: RCUS real-time stock quote data, in-depth charts, free RCUS options chain data, and a fully built financial calendar to help you invest smart. Buy RCUS stock at Webull.Jul 11, 2023 · HAYWARD, Calif., July 11, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ... HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth-quarter and full-year ended December 31, 2022 and provided a pipeline update on its six clinical-stage investigational molecules ...HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...Arcus Biosciences Inc (NYSE: RCUS) argenx SE – ADR (NASDAQ: ARGX) Atea Pharmaceuticals Inc (NASDAQ: AVIR) BioVie Inc (NASDAQ: BIVI) C4 Therapeutics Inc (NASDAQ: CCCC)Shares of Arcus Biosciences ( RCUS 3.94%) jumped by as much as 21% in premarket trading Thursday morning. The biotech's stock is heating up in early morning action today on the news that Gilead ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat ...Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, recently reported financial results for the third quarter ended September 30, 2022 and provided a pipeline update on its six clinical …HAYWARD, Calif., October 10, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...Nov 24, 2023 · A high-level overview of Arcus Biosciences, Inc. (RCUS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Gilead Sciences, Inc. (Nasdaq:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced that the companies have expanded the previously announced

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...Cantor Fitzgerald Adjusts Arcus Biosciences' Price Target to $36 From $46, Maintains Overweight Rating. Nov. 08. MT. Transcript : Arcus Biosciences, Inc., Q3 2023 …

Source Headline; From laggards to leaders: Small caps on the rise (RCUS) marketbeat.com - November 27 at 8:45 AM Brokerages Set Arcus Biosciences, Inc. …HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...NYSE RCUS, also known as Renovacor, is a biotechnology company listed on the New York Stock Exchange (NYSE) under the ticker symbol RCUS. Renovacor focuses on developing gene therapies for cardiovascular diseases, aiming to provide effective treatments for patients suffering from debilitating conditions such as dilated …NYSE RCUS, also known as Renovacor, is a biotechnology company listed on the New York Stock Exchange (NYSE) under the ticker symbol RCUS. Renovacor focuses on developing gene therapies for cardiovascular diseases, aiming to provide effective treatments for patients suffering from debilitating conditions such as dilated …Real time Arcus Biosciences (RCUS) stock price quote, stock graph, news & analysis. Nov 10, 2023 · The following insider purchased RCUS shares in the last 24 months: Gilead Sciences, Inc. ($19,452,600.00). How much insider buying is happening at Arcus Biosciences? Insiders have purchased a total of 1,010,000 RCUS shares in the last 24 months for a total of $19,452,600.00 bought. Arcus Biosciences, Inc. , an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of...Arcus Biosciences has raised a total of. $647.1M. in funding over 5 rounds. Their latest funding was raised on Feb 1, 2021 from a Post-IPO Equity round. Arcus Biosciences is registered under the ticker NYSE:RCUS . Their stock opened with $15.00 in its Mar 14, 2018 IPO. Arcus Biosciences is funded by 18 investors.Jul 11, 2023 · HAYWARD, Calif., July 11, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Arcus Biosciences, Inc. SÀN CHỨNG KHOÁN / STOCK EXCHANGE NYSE (US). MÃ CHỨNG KHOÁN / TICKER RCUS. KỲ BÁO CÁO 2022. NGÀNH / INDUSTRY Biotechnology. LĨNH VỰC ...

NYSE Composite Today: Get all information on the NYSE Composite Index including historical chart, news and constituents. Indices Commodities Currencies Stocks

Source Headline; From laggards to leaders: Small caps on the rise (RCUS) marketbeat.com - November 27 at 8:45 AM Brokerages Set Arcus Biosciences, Inc. …BNP Paribas Arbitrage SNC lessened its holdings in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 61.6% during the 2nd quarter, according to its most recent filing with the Securities and ...Dec 4, 2023 · The RCUS shares have gain 14.30% over the last week, with a monthly amount glided 1.58%, and seem At the time of writing, Arcus Biosciences Inc [RCUS] stock is trading at $16.07, up 6.71%. It is a good measure of the stock's recent performance to check whether the stock's short-term value is rising or falling. HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...The new research reports from Market Source Research, available for free download at the links above, examine Arcus Biosciences, Inc. (NYSE:RCUS), Ion Geophysical Corporation (NYSE:IO), A.H. Belo ...FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today that the companies have entered into a 10-year partnership to co …HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced seven accepted abstracts at the 2023 American Society of Clinical Oncology (ASCO) …Source. Headline. From laggards to leaders: Small caps on the rise (RCUS) marketbeat.com - November 27 at 8:45 AM. Brokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) Price Target at $43.13. americanbankingnews.com - November 26 at 2:30 AM. Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey. seekingalpha.com - November 20 at 5:46 PM.October 01, 2020 04:41 PM Eastern Daylight Time. HAYWARD, Calif.-- ( BUSINESS WIRE )--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in ...Shares of Arcus Biosciences ( RCUS 3.13%), a clinical-stage biopharmaceutical company, are on the move following a progress report for the company's most valuable asset at the moment. Investors ...Nov 23, 2023 · Arcus Biosciences Stock Performance. NYSE RCUS opened at $13.87 on Thursday. Arcus Biosciences has a one year low of $12.95 and a one year high of $36.13. The firm’s fifty day moving average is $16.47 and its two-hundred day moving average is $18.74. The firm has a market cap of $1.04 billion, a PE ratio of -3.47 and a beta of 0.76.

Currently, Arcus Biosciences Inc [RCUS] is trading at $14.62, up 3.32%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RCUS shares have gain 5.87% over the last week, with a monthly amount drifted -2.21%, and not seem to be holding up well overArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to …Cantor Fitzgerald Adjusts Arcus Biosciences' Price Target to $36 From $46, Maintains Overweight Rating. Nov. 08. MT. Transcript : Arcus Biosciences, Inc., Q3 2023 Earnings Call, Nov 07, 2023. Nov. 07. CI. Earnings Flash (RCUS) ARCUS BIOSCIENCES Posts Q3 Revenue $32M, vs. Street Est of $27.6M. Nov. 07.Mar 23, 2023 · Arcus Biosciences ( NYSE: RCUS) is a biopharmaceutical company specializing in cancer therapeutics that are operating at the clinical stage. Their lead candidate, domvanalimab, has displayed ... Instagram:https://instagram. firstwesterntrustatraebrokers for day tradingtodays market movers Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the third quarter ended September 30, 2023, and provided a pipeline update on its clinical-stage investigational molecules ... stamp price 2022jotit The latest price target for Arcus Biosciences ( NYSE: RCUS) was reported by Cantor Fitzgerald on Thursday, September 7, 2023. The analyst firm set a price target for 46.00 expecting RCUS to rise ... how to create a trust for property NYSE - NYSE Delayed Price. Currency in USD Follow 2W 10W 9M 14.49 +0.44 (+3.13%) At close: 04:00PM EST 14.63 +0.14 (+0.97%) Pre-Market: 07:28AM EST 1d 5d 1m 6m YTD 1y 5y Max Full screen Trade...HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...